An interventional study of Discontinuation of dornase alfa (Dnase) and Continuation of dornase alfa (Dnase) in Cystic Fibrosis, sponsored by Nicole Hamblett. Completed at 81 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2024-11-26.
Sponsored by Nicole Hamblett · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 717 studies in Cystic Fibrosis with a site in United States — 85 open to participants now, 111 under way, 8 of them phase 3. Cystic Fibrosis · United States.
Among the 717 studies in Cystic Fibrosis with a site in United States, this one is the 18th largest by enrollment of the 517 interventional ones that give a count, is one of 34 that started in 2020, is one of 155 with no phase, and was the 665th registered.
1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →85 of the 717 studies in Cystic Fibrosis with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
Aimmune Nestlé Health Science US R&D, LLC · Sites in United States, Bulgaria, Hungary and 4 more countries
Ages 18–85
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 3–18
Ghady Haidar · Sites in United States
Ages 18+
Anagram Therapeutics, Inc. · Sites in United States
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
717 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 109 · Phase 2 143 · Phase 3 108 · Phase 4 47
First in 1988; this study’s year is marked. 34 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 477 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 36 across the 517 interventional studies, 80 across the 193 observational. Of the 569 that completed or were terminated, 263 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
250 of 717 have an industry lead sponsor. The 10 most frequent:
Nicole Hamblett is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Nicole Hamblett has 8 studies filed under Cystic Fibrosis — fewer than ten, so there is no comparison to draw.
43 of the studies in Cystic Fibrosis with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06413368Phase 3Children's Hospital Los AngelesMaralixibat in Patients With Cystic Fibrosis and Constipation | 2027-06-30 |
| NCT06449677Phase 3Jaeb Center for Health ResearchBionic Pancreas in CFRD | 2027-06-30 |
| NCT06996951Phase 3Indiana UniversitySinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy | 2027-07 |
| NCT06237335ReCode TherapeuticsA Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF | 2026-11 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
Add all 43 to your calendar (.ics) → With an account.
Among the 717 studies in Cystic Fibrosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Despite the increasingly common use of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies in treating cystic fibrosis (CF), it is still largely unknown whether or not other chronic therapies can be safely stopped. This SIMPLIFY sub-study is being done to test whether or not it is safe to stop taking dornase alfa (Dnase) in those people that are also taking elexacaftor/tezacaftor/ivacaftor (ETI).
ETI is a combination CFTR modulator therapy that was approved by the Food and Drug Administration for people with CF who have at least one F508del mutation. The three drugs that make up ETI work together to allow many more chloride ions to move into and out of the cells, improving the balance of salt and water in the lungs. These changes result in better clearance of mucus from the lungs and improvements in lung function.
Dornase alfa (Dnase) also improves clearance of mucus from the lungs to support lung function and has been available to people with CF for many years. Dnase is considered to be relatively burdensome and it is not known whether Dnase can improve or maintain lung function above what is already gained through ETI use.
The goal of this SIMPLIFY sub-study is to get information about whether or not it is safe to stop Dnase by testing if there is a change in lung function in participants with cystic fibrosis (CF) who are assigned to stop taking Dnase as compared to those who are assigned to keep taking Dnase while continuing to take ETI.
This is a sub study of master protocol SIMPLIFY-IP-19, NCT04378153.
The sub study investigating the impact of discontinuing and continuing hypertonic saline is registered under NCT06350461.
This SIMPLIFY sub-study (Dornase Alfa (Dnase) Trial) is designed to evaluate the effects of discontinuing Dnase in people with cystic fibrosis (CF) age 12 and older currently taking the highly effective modulator elexacaftor/tezacaftor/ivacaftor (ETI). This is an open label two-arm randomized non-inferiority trial consisting of a 2-week screening period, randomization to continue or discontinue dornase alfa, followed by a 6-week study period. Participants at trial entry will be randomized 1:1 to either continue or discontinue their Dnase therapy.
Clinical outcomes (forced expiratory volume in 1 second [FEV1], antibiotic use, pulmonary exacerbations, and patient reported outcomes), safety (adverse events) and patient reported outcomes to evaluate respiratory symptoms and the participant's perception of how stopping Dnase would impact their daily life will be evaluated in all subjects. Additionally, a subset of participants at selected study sites will participate in Multiple Breath Washout (MBW) to evaluate changes in lung clearance index (LCI).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Discontinuation of current dornase alfa (dnase) therapy
Other: Discontinuation of dornase alfa (Dnase)
Continuation of current dornase alfa (dnase) therapy
Other: Continuation of dornase alfa (Dnase)
Discontinuation of current dornase alfa (Dnase) therapy during 6-week study period.
Continuation of current dornase alfa (dnase) therapy during 6-week study period. Therapy is taken at least once daily according to each participant's pre-existing, clinically prescribed regimen (e.g., daily, twice daily)
Absolute Change in FEV1 % Predicted From Week 0 to Week 6
Non-Inferiority statistical testing compared difference between study arms (discontinue - continue) in the absolute change in FEV1 % predicted from Week 0 to Week 6.
Time frame: Week 0 to Week 6
Absolute Change in LCI 2.5 From Baseline to Week 6
Statistical testing compared difference between study arms (discontinue - continue) in the absolute change in LCI 2.5 (Lung Clearance Index) from Baseline (Week 0, if available, or else Week -2) to Week 6. LCI 2.5 is the number of times the volume in the lungs needs to turn over to expel an inert gas. A higher value of LCI 2.5 indicates poorer lung function.
Time frame: Baseline (Week 0 or Week -2) to Week 6
Absolute Change in Respiratory Symptoms, as Measured by the CF Respiratory Symptoms Diary-Chronic Respiratory Infection Symptom Severity Score (CRISS) From Week 0 to Week 6
Statistical testing compared the difference between study arms (discontinue - continue) in the absolute change in respiratory symptoms, as measured by the CF Respiratory Symptoms Diary-Chronic Respiratory Infection Symptom Severity Score (CRISS) from Week 0 to Week 6. The Cystic Fibrosis Respiratory Symptoms Daily Diary (CFRSD) asks a participant to state the extent of their 8 respiratory symptoms: difficulty breathing, feverishness, tiredness, chills or sweats, coughing, coughing up mucus, tightness in the chest and wheezing. Each respiratory symptom is assigned a score from 0-4 based on the response, with zero corresponding to the absence of the symptom and four corresponding to symptom being present 'a great deal' or 'extremely'. A summed score (range from 0-24) is calculated for each participant and converted to a final score with a range of 0 to 100 where the lowest scores indicate improvement of symptoms. Calculation of a score requires responses for at least 7 out of 8 symptoms
Time frame: Week 0 to Week 6
Absolute Change in Respiratory Symptoms, as Measured by CFQ-R Respiratory Domain From Week 0 to Week 6
Statistical testing compared the difference between study arms (discontinue - continue) in the absolute change in respiratory symptoms, as measured by the Cystic Fibrosis Questionnaire-Revised Respiratory Domain Score from Week 0 to Week 6. The Cystic Fibrosis Questionnaire - Revised asks participants 6 questions related to respiratory symptoms which are each assigned a score 1-4. The Respiratory Domain Scaled Score is calculated as follows: 100\*\[{sum of responses}/{number of responses}-1\]/3 only if number of responses ≥ 3; otherwise the score is set to missing. The scaled score ranges from 0 to 100 where higher scores indicate improvement of symptoms.
Time frame: Week 0 to Week 6
Absolute Change in FEV1 % Predicted From Week -2 to Week 0
Statistical testing compared the difference between study arms (discontinue - continue) in the absolute change in FEV1 % predicted from Week -2 to Week 0.
Time frame: Week -2 to Week 0
Absolute Change in FEV1 % Predicted From Week 0 to Week 2
Statistical testing compared the difference between study arms (discontinue - continue) in the absolute change in FEV1 % predicted from Week 0 to Week 2.
Time frame: Week 0 to Week 2
Number and Percent of Participants Initiating Acute Antibiotics From Week 0 to Week 6
Difference between study arms (discontinue - continue) in the percent of subjects initiating acute oral, inhaled or intravenous antibiotics from Week 0 to Week 6. Includes antibiotics initiated for respiratory indications; excludes those taken as part of a chronic cycled regimen or for a UTI, skin infection, etc.
Time frame: Week 0 to Week 6
Number and Percent of Participants Hospitalized From Week 0 to Week 6
Statistical testing compared the difference between study arms (discontinue - continue) in the percent of subjects hospitalized from Week 0 to Week 6.
Time frame: Week 0 to Week 6
Number and Percent of Participants Experiencing Pulmonary Exacerbations From Week 0 to Week 6
Statistical testing compared the difference between study arms (discontinue - continue) in the percent of subjects experiencing a pulmonary exacerbation from Week 0 to Week 6. Pulmonary exacerbations defined using Fuchs criteria.
Time frame: Week 0 to Week 6
Number and Percent of Participants Experiencing Adverse Events (AEs) From Week 0 to Week 6
Statistical testing compared the difference between study arms (discontinue - continue) in the percent of participants with at least one AE from Week 0 to Week 6. Includes serious and non-serious AEs.
Time frame: Week 0 to Week 6
Rate of Adverse Events (AEs) From Week 0 to Week 6 Therapy Arms
Statistical testing compared the compared the rate of AE occurrence (number of events divided by total follow-up weeks in each arm) between study arms from Week 0 to Week 6. Includes serious and non-serious AEs.
Time frame: Week 0 to Week 6
Number and Percent of Participants With Temporary or Permanent Changes From Assigned Therapy Regimen Due to Adverse Event From Week 0 to Week 6
Statistical testing compared the difference between study arms (discontinue - continue) in the percent of subjects temporarily or permanently changing their assigned therapy regimen due to an adverse event Week 0 to Week 6
Time frame: Week 0 to Week 6
| Milestone | Dnase - Discontinue | Dnase - Continue |
|---|---|---|
| Started | 240 | 237 |
| Completed | 238 | 236 |
| Not completed | 2 | 1 |
Non-Inferiority statistical testing compared difference between study arms (discontinue - continue) in the absolute change in FEV1 % predicted from Week 0 to Week 6.
| FEV1 % predicted | Dnase - Discontinue | Dnase - Continue |
|---|---|---|
| Absolute Change in FEV1 % Predicted From Week 0 to Week 6 | 0.2 ± 3.69 | -0.2 ± 4.37 |
Statistical testing compared difference between study arms (discontinue - continue) in the absolute change in LCI 2.5 (Lung Clearance Index) from Baseline (Week 0, if available, or else Week -2) to Week 6. LCI 2.5 is the number of times the volume in the lungs needs to turn over to expel an inert gas. A higher value of LCI 2.5 indicates poorer lung function.
| number of lung volume turnovers | Dnase - Discontinue | Dnase - Continue |
|---|---|---|
| Absolute Change in LCI 2.5 From Baseline to Week 6 | -0.1 ± 0.63 | 0.0 ± 0.56 |
Statistical testing compared the difference between study arms (discontinue - continue) in the absolute change in respiratory symptoms, as measured by the CF Respiratory Symptoms Diary-Chronic Respiratory Infection Symptom Severity Score (CRISS) from Week 0 to Week 6. The Cystic Fibrosis Respiratory Symptoms Daily Diary (CFRSD) asks a participant to state the extent of their 8 respiratory symptoms: difficulty breathing, feverishness, tiredness, chills or sweats, coughing, coughing up mucus, tightness in the chest and wheezing. Each respiratory symptom is assigned a score from 0-4 based on the response, with zero corresponding to the absence of the symptom and four corresponding to symptom being present 'a great deal' or 'extremely'. A summed score (range from 0-24) is calculated for each participant and converted to a final score with a range of 0 to 100 where the lowest scores indicate improvement of symptoms. Calculation of a score requires responses for at least 7 out of 8 symptoms
| score on a scale | Dnase - Discontinue | Dnase - Continue |
|---|---|---|
| Absolute Change in Respiratory Symptoms, as Measured by the CF Respiratory Symptoms Diary-Chronic Respiratory Infection Symptom Severity Score (CRISS) From Week 0 to Week 6 | -0.1 ± 9.49 | -1.1 ± 10.21 |
Statistical testing compared the difference between study arms (discontinue - continue) in the absolute change in respiratory symptoms, as measured by the Cystic Fibrosis Questionnaire-Revised Respiratory Domain Score from Week 0 to Week 6. The Cystic Fibrosis Questionnaire - Revised asks participants 6 questions related to respiratory symptoms which are each assigned a score 1-4. The Respiratory Domain Scaled Score is calculated as follows: 100\*\[{sum of responses}/{number of responses}-1\]/3 only if number of responses ≥ 3; otherwise the score is set to missing. The scaled score ranges from 0 to 100 where higher scores indicate improvement of symptoms.
| score on a scale | Dnase - Discontinue | Dnase - Continue |
|---|---|---|
| Absolute Change in Respiratory Symptoms, as Measured by CFQ-R Respiratory Domain From Week 0 to Week 6 | -0.9 ± 6.23 | 0.0 ± 8.85 |
Statistical testing compared the difference between study arms (discontinue - continue) in the absolute change in FEV1 % predicted from Week -2 to Week 0.
| FEV1 % predicted | Dnase - Discontinue | Dnase - Continue |
|---|---|---|
| Absolute Change in FEV1 % Predicted From Week -2 to Week 0 | 0.2 ± 3.11 | 0.0 ± 3.79 |
Statistical testing compared the difference between study arms (discontinue - continue) in the absolute change in FEV1 % predicted from Week 0 to Week 2.
| FEV1 % predicted | Dnase - Discontinue | Dnase - Continue |
|---|---|---|
| Absolute Change in FEV1 % Predicted From Week 0 to Week 2 | -0.1 ± 3.67 | 0.1 ± 3.96 |
Difference between study arms (discontinue - continue) in the percent of subjects initiating acute oral, inhaled or intravenous antibiotics from Week 0 to Week 6. Includes antibiotics initiated for respiratory indications; excludes those taken as part of a chronic cycled regimen or for a UTI, skin infection, etc.
| Participants | Dnase - Discontinue | Dnase - Continue |
|---|---|---|
| Number and Percent of Participants Initiating Acute Antibiotics From Week 0 to Week 6 | 14 | 8 |
Statistical testing compared the difference between study arms (discontinue - continue) in the percent of subjects hospitalized from Week 0 to Week 6.
| Participants | Dnase - Discontinue | Dnase - Continue |
|---|---|---|
| Number and Percent of Participants Hospitalized From Week 0 to Week 6 | 0 | 0 |
Statistical testing compared the difference between study arms (discontinue - continue) in the percent of subjects experiencing a pulmonary exacerbation from Week 0 to Week 6. Pulmonary exacerbations defined using Fuchs criteria.
| Participants | Dnase - Discontinue | Dnase - Continue |
|---|---|---|
| Number and Percent of Participants Experiencing Pulmonary Exacerbations From Week 0 to Week 6 | 4 | 2 |
Statistical testing compared the difference between study arms (discontinue - continue) in the percent of participants with at least one AE from Week 0 to Week 6. Includes serious and non-serious AEs.
| Participants | Dnase - Discontinue | Dnase - Continue |
|---|---|---|
| Number and Percent of Participants Experiencing Adverse Events (AEs) From Week 0 to Week 6 | 89 | 55 |
Statistical testing compared the compared the rate of AE occurrence (number of events divided by total follow-up weeks in each arm) between study arms from Week 0 to Week 6. Includes serious and non-serious AEs.
| events per week | Dnase - Discontinue | Dnase - Continue |
|---|---|---|
| Rate of Adverse Events (AEs) From Week 0 to Week 6 Therapy Arms | 0.116 | 0.060 |
Statistical testing compared the difference between study arms (discontinue - continue) in the percent of subjects temporarily or permanently changing their assigned therapy regimen due to an adverse event Week 0 to Week 6
| Participants | Dnase - Discontinue | Dnase - Continue |
|---|---|---|
| Number and Percent of Participants With Temporary or Permanent Changes From Assigned Therapy Regimen Due to Adverse Event From Week 0 to Week 6 | 7 | 2 |
Collected over From randomization (Week 0) up to last study visit (Week 6), i.e., 6 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dnase - Discontinue | 0/240 (0%) | 0/240 (0%) | 25/240 (10.4%) |
| Dnase - Continue | 0/237 (0%) | 0/237 (0%) | 14/237 (5.9%) |
| Event | Dnase - Discontinue | Dnase - Continue |
|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 16/240 | 10/237 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 11/240 | 4/237 |
Primary analyses were done on the per-protocol (PP) population.
| Age, Continuous(years) | Dnase - Discontinue | Dnase - Continue | Total |
|---|---|---|---|
| Mean | 22.1 ± 9.39 | 23.7 ± 11.83 | 22.9 ± 10.7 |
| Age, Customized(Participants) | Dnase - Discontinue | Dnase - Continue | Total |
|---|---|---|---|
| Age Distribution (years) — >=12 to <18 | 89 | 85 | 174 |
| Age Distribution (years) — >=18 to <24 | 45 | 36 | 81 |
| Age Distribution (years) — >=24 to <30 | 25 | 27 | 52 |
| Age Distribution (years) — >=30 | 40 | 45 | 85 |
| Sex: Female, Male(Participants) | Dnase - Discontinue | Dnase - Continue | Total |
|---|---|---|---|
| Female | 98 | 97 | 195 |
| Male | 101 | 96 | 197 |
| Race/Ethnicity, Customized(Participants) | Dnase - Discontinue | Dnase - Continue | Total |
|---|---|---|---|
| Race — White | 192 | 187 | 379 |
| Race — Black or African American | 1 | 3 | 4 |
| Race — Asian | 0 | 1 | 1 |
| Race — American Indian or Alaskan Native | 1 | 0 | 1 |
| Race — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Race — Other, More than One Race, or Unknown/Not Reported | 5 | 2 | 7 |
| Cystic Fibrosis (CF) Genotype(Participants) | Dnase - Discontinue | Dnase - Continue | Total |
|---|---|---|---|
| F508del Homozygous | 105 | 115 | 220 |
| F508del Heterozygous | 90 | 73 | 163 |
| Other or Unknown | 4 | 5 | 9 |
| Forced Expiratory Volume in 1 second (FEV1)(liters) | Dnase - Discontinue | Dnase - Continue | Total |
|---|---|---|---|
| Mean | 3.3 ± 0.88 | 3.3 ± 0.86 | 3.3 ± 0.87 |
| FEV1 (% Predicted)(percent predicted) | Dnase - Discontinue | Dnase - Continue | Total |
|---|---|---|---|
| Mean | 96.8 ± 17.40 | 97.0 ± 16.35 | 96.9 ± 16.87 |
| FEV1 (% Predicted) Distribution(Participants) | Dnase - Discontinue | Dnase - Continue | Total |
|---|---|---|---|
| <60 | 1 | 3 | 4 |
| >=60 to <70 | 16 | 10 | 26 |
| >=70 to <90 | 46 | 48 | 94 |
| >=90 to <100 | 42 | 42 | 84 |
| >=100 | 94 | 90 | 184 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2020 to primary completion in Jul 2022, 22 months.
Results were first posted in Nov 2024, 2 years 4 months after primary completion.
Of 214 non-industry interventional studies with no phase under Cystic Fibrosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's 22 months is close to that.
Counting every sponsor, half of 229 studies reached it within 24 months; a quarter within 12 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nicole Hamblett